Loading clinical trials...
Loading clinical trials...
Relation Between Gastrocnemius Muscle Architecture and Functional Ability in Ambulatory Children With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a progressive X-linked neuromuscular disorder characterized by muscle degeneration, pseudohypertrophy, and declining functional mobility. This cross-sectional observational study investigates the relationship between gastrocnemius muscle architecture and functional ability in ambulatory children with DMD. Muscle thickness and fascicle length were assessed using ultrasonography and correlated with motor function and ankle plantarflexion during gait.
Duchenne Muscular Dystrophy (DMD) is a genetic neuromuscular disorder characterized by progressive muscle degeneration, fatty infiltration, fibrosis, and loss of functional capacity during childhood. Although pseudohypertrophy may cause apparent enlargement of calf muscles, structural changes do not necessarily reflect muscle quality or functional performance. This cross-sectional observational study included 26 ambulatory male children aged 6 to 12 years diagnosed with DMD. Participants underwent a single comprehensive assessment session. Muscle architecture of the medial gastrocnemius muscle was evaluated using 2-dimensional ultrasonography (Mindray DP-10, 7.5 MHz probe) to measure muscle thickness and fascicle length. Functional ability was assessed using: * The Motor Function Measure (MFM-32) * The Vignos Scale * Timed 10-Meter Walk Test Ankle plantarflexion range of motion during gait was measured using Kinovea motion analysis software with 2D digital video analysis. Correlation analysis was performed to determine the relationship between muscle architectural parameters and functional ability measures. No therapeutic intervention, randomization, or group allocation was performed.
Age
6 - 12 years
Sex
MALE
Healthy Volunteers
No
Deraya university, faculty of physical therapy
Minya, Menia Governorate, Egypt
Start Date
September 10, 2024
Primary Completion Date
October 31, 2025
Completion Date
November 10, 2025
Last Updated
February 27, 2026
26
ACTUAL participants
Lead Sponsor
Deraya University
NCT07037862
NCT07129954
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06925269